Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Extends Wyeth, Progenics NDA Review For Methylnaltrexone Until April

This article was originally published in The Pink Sheet Daily

Executive Summary

Additional three months of review will push methylnaltrexone action date behind GSK/Adolor’s Entereg.

You may also be interested in...



Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too

Compound helps bowel function in dying patients on opioids.

Wyeth/Progenics’ Relistor: FDA Says Yes, EU Likes It, Too

Compound helps bowel function in dying patients on opioids.

Daily Cost of Wyeth’s Pristiq For Depression Beats Effexor By 20 Percent

50 mg and 100 mg Pristiq tablets will be sold for a flat rate of $3.41, firm announces during an April 22 first quarter sales and earnings call.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel